変形性関節症治療薬市場：解剖学、薬剤タイプ、投与経路、購買パターン、流通チャネル別-2025-2030年世界予測

変形性関節症治療薬市場は、2023年に79億米ドルと評価され、2024年には86億9,000万米ドルに達すると予測され、CAGR 10.39％で成長し、2030年には157億8,000万米ドルに達すると予測されています。

変形性関節症治療薬は、軟骨の破壊を特徴とする退行性関節疾患である変形性関節症の症状を緩和し、進行を遅らせることを目的とした幅広い治療法を指します。NSAIDs、コルチコステロイド、鎮痛剤などの医薬品、生物学的製剤、遺伝子治療や幹細胞治療などの新しい治療法が含まれるが、これらに限定されるものではないです。これらの治療薬の必要性は、高齢化、肥満率の増加、ライフスタイルの変化などにより、世界中で変形性関節症の有病率が増加していることに起因しています。これらの治療薬は、痛みや炎症を軽減し、関節機能を改善するためのもので、主にクリニックや病院、在宅ヘルスケアで使用される罹患者を対象としています。市場の成長は、技術の進歩、研究開発投資の増加、早期リハビリテーションに対する意識の高まりに影響されています。さらに、併用療法や低侵襲手技の開発が大きな機会をもたらしています。企業は、革新的技術への投資や、戦略的提携・買収による製品ポートフォリオの拡大により、資本を増強することができます。しかし、高額な治療費、厳しい規制要件、潜在的な副作用は、市場拡大の制約となります。技術革新と研究は、費用対効果が高く、患者にやさしく、副作用の少ない標的治療法の開発に焦点を当てるべきです。創薬にAIや機械学習を活用し、個々の患者プロファイルに合わせた個別化医療を開発することは、競争優位性をもたらす可能性があります。市場情勢はダイナミックであり、急速な進歩と常に適応を必要とする競合情勢が特徴です。病気のメカニズムを理解し、デリバリーシステムを改善するための高度な調査に投資している企業は、おそらく成功を収めると思われます。有望な市場である一方、規制上の課題を克服し、より多くの患者層に行き渡るよう手頃な価格を確保することが必要であり、変形性関節症管理への幅広いアクセスと教育を促進するための政府機関やヘルスケア機関との協力の必要性が浮き彫りになっています。

市場力学：急速に進化する変形性関節症治療薬市場の主要市場インサイトを公開

変形性関節症治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界中で増加する変形性関節症の有病率
  • 低侵襲手術に対する潜在的需要
  • 世界のスポーツ傷害の増加と相まって増加する老人人口
• 市場抑制要因
  • NSAIDの副作用に関する懸念
• 市場機会
  • 変形性関節症に対する新たな医薬品療法
  • 変形性関節症分野における継続的な研究開発
  • 変形性関節症治療に対する政府支援の増加
  • 新興国における一人当たり医療費の増加
• 市場の課題
  • 非薬物疼痛管理療法の急速な普及

ポーターの5つの力：変形性関節症治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：変形性関節症治療薬市場における外部からの影響の把握

外部マクロ環境要因は、変形性関節症治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析変形性関節症治療薬市場における競合情勢の把握

変形性関節症治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス変形性関節症治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、変形性関節症治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨変形性関節症治療薬市場における成功への道筋を描く

変形性関節症治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で変形性関節症の罹患率が上昇
    • 低侵襲手術の潜在的需要
    • 高齢化人口の増加と世界中でスポーツによる傷害の増加
  • 抑制要因
    • NSAIDの副作用に関する懸念
  • 機会
    • 変形性関節症に対する新たな医薬品治療法
    • 変形性関節症分野における継続的な研究開発
    • 変形性関節症治療に対する政府の支援の強化
    • 新興国における一人当たりヘルスケア費の上昇
  • 課題
    • 非薬物性疼痛管理療法の急速な導入
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 変形性関節症治療薬市場解剖学別

• 手の変形性関節症
• 変形性股関節症
• 変形性膝関節症
• 小関節変形性関節症

第7章 変形性関節症治療薬市場薬の種類別

• 鎮痛剤
  • アセトアミノフェン
  • デュロキセチン
• コルチコステロイド
• 非ステロイド性抗炎症薬
  • アスピリン
  • ジクロフェナク
  • イブプロフェン
  • ナプロキセン
• 関節内補充療法剤

第8章 変形性関節症治療薬市場：投与経路別

• 経口投与
• 非経口投与
• 局所経路

第9章 変形性関節症治療薬市場購入パターン別

• 市販薬
• 処方薬

第10章 変形性関節症治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第11章 南北アメリカの変形性関節症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の変形性関節症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの変形性関節症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Almatica Pharma LLC
• Anika Therapeutics, Inc.
• Assertio Therapeutics, Inc.
• Atnahs Pharma UK Limited
• Bayer AG
• Bioventus
• Eli Lilly and Company
• Ferring B.V.
• Fidia Farmaceutici s.p.a.
• Flexion Therapeutics, Inc.
• GlaxoSmithKline PLC
• Hanmi Pharm. Co., Ltd.
• Horizon Therapeutics PLC
• Kitov Pharmaceuticals Ltd.

LIST OF FIGURES

• FIGURE 1. OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. OSTEOARTHRITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. OSTEOARTHRITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. OSTEOARTHRITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. OSTEOARTHRITIS THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HAND OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HIP OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY KNEE OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SMALL JOINT OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DULOXETINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY VISCOSUPPLEMENTATION AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL ROUTE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PARENTERAL ROUTE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL ROUTE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 59. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 61. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 62. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 64. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 88. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 96. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 97. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 98. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 99. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 101. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 103. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 104. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 105. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 106. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 108. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. INDONESIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 115. INDONESIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 122. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. MALAYSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 127. MALAYSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. MALAYSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 129. MALAYSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. PHILIPPINES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 134. PHILIPPINES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. PHILIPPINES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 136. PHILIPPINES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. SINGAPORE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 141. SINGAPORE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. SINGAPORE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 143. SINGAPORE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 148. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 150. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 151. TAIWAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 155. TAIWAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 156. TAIWAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 157. TAIWAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 158. THAILAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 162. THAILAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. THAILAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 164. THAILAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 165. VIETNAM OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 169. VIETNAM OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 170. VIETNAM OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 171. VIETNAM OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 172. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 179. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 180. DENMARK OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 184. DENMARK OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. DENMARK OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 186. DENMARK OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. EGYPT OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 191. EGYPT OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 192. EGYPT OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 193. EGYPT OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. FINLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 198. FINLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 199. FINLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 200. FINLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 201. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 205. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 206. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 207. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 208. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 212. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 213. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 214. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 215. ISRAEL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 219. ISRAEL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 220. ISRAEL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 221. ISRAEL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 222. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 223. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 224. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 225. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 226. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 227. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 228. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 229. NETHERLANDS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 233. NETHERLANDS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 234. NETHERLANDS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 235. NETHERLANDS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 236. NIGERIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 240. NIGERIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 241. NIGERIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 242. NIGERIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 243. NORWAY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 244. NORWAY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 245. NORWAY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 246. NORWAY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 247. NORWAY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 248. NORWAY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 249. NORWAY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 250. POLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 251. POLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 252. POLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 253. POLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 254. POLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 255. POLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 256. POLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 257. QATAR OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 258. QATAR OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 259. QATAR OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 260. QATAR OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 261. QATAR OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 262. QATAR OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 263. QATAR OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 264. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 265. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 266. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 267. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 268. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 269. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 270. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 271. SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 272. SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 273. SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 274. SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 275. SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 276. SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 277. SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 278. SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 279. SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 280. SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 281. SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 282. SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 283. SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 284. SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 285. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 286. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 287. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 288. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 289. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 290. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 291. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 292. SWEDEN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 293. SWEDEN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 294. SWEDEN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 295. SWEDEN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 296. SWEDEN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 297. SWEDEN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 298. SWEDEN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 299. SWITZERLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANATOMY, 2018-2030 (USD MILLION)
• TABLE 300. SWITZERLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 301. SWITZERLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
• TABLE 302. SWITZERLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
• TABLE 303. SWITZERLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 304. SWITZERLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PURCHASING PATTERN, 2018-2030 (USD MILLION)
• TABLE 305. SWITZERLAND OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 306. TURKEY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ANA

The Osteoarthritis Therapeutics Market was valued at USD 7.90 billion in 2023, expected to reach USD 8.69 billion in 2024, and is projected to grow at a CAGR of 10.39%, to USD 15.78 billion by 2030.

Osteoarthritis therapeutics refer to a wide array of treatments designed to alleviate the symptoms and slow the progression of osteoarthritis, a degenerative joint disease characterized by the breakdown of cartilage. The scope includes but is not limited to pharmaceuticals like NSAIDs, corticosteroids, and analgesics, biologics, and emerging therapies such as gene therapy and stem cell treatment. The necessity for these therapeutics arises from the growing prevalence of osteoarthritis worldwide, driven by an aging population, increased obesity rates, and lifestyle changes. These therapeutics find application in reducing pain, inflammation, and improving joint function, primarily targeting affected individuals for use at clinics, hospitals, and home healthcare settings. Market growth is influenced by technological advancements, increasing R&D investments, and a rising awareness of early rehabilitation. Furthermore, the development of combination therapies and minimally invasive procedures present significant opportunities. Companies can capitalize by investing in innovative technologies and expanding their product portfolios through strategic partnerships and acquisitions. However, high treatment costs, stringent regulatory requirements, and potential side effects present limitations to market expansion. Innovation and research should focus on developing cost-effective, patient-friendly, and targeted treatment options with reduced side effects. Leveraging AI and machine learning for drug discovery and developing personalized medicine tailored to individual patient profiles could offer competitive advantages. The osteoarthritis therapeutics market is dynamic, characterized by rapid advancements and a competitive landscape necessitating constant adaptation. Companies investing in advanced research to understand the disease mechanisms and improve delivery systems will likely thrive. While promising, the market requires navigating regulatory challenges and ensuring affordability to reach a broader patient base, underscoring the need for collaboration with government bodies and healthcare institutions to facilitate widespread access and education on osteoarthritis management.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Osteoarthritis Therapeutics Market

The Osteoarthritis Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of osteoarthritis across the globe
  • Potential demand for minimally invasive surgical procedures
  • Growing geriatric population coupled with increasing sports injury worldwide
• Market Restraints
  • Concern associated with adverse effects of NSAID
• Market Opportunities
  • Emerging pharmaceuticals therapies for osteoarthritis
  • Ongoing research and development in the osteoarthritis field
  • Increasing governments supports towards the osteoarthritis treatment
  • Rising healthcare expenditure per capita income in the emerging economies
• Market Challenges
  • Rapid adoption of non-drug pain management therapies

Porter's Five Forces: A Strategic Tool for Navigating the Osteoarthritis Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Osteoarthritis Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Osteoarthritis Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Osteoarthritis Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Osteoarthritis Therapeutics Market

A detailed market share analysis in the Osteoarthritis Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Osteoarthritis Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Osteoarthritis Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Osteoarthritis Therapeutics Market

A strategic analysis of the Osteoarthritis Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Osteoarthritis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Almatica Pharma LLC, Anika Therapeutics, Inc., Assertio Therapeutics, Inc., Atnahs Pharma UK Limited, Bayer AG, Bioventus, Eli Lilly and Company, Ferring B.V., Fidia Farmaceutici s.p.a., Flexion Therapeutics, Inc., GlaxoSmithKline PLC, Hanmi Pharm. Co., Ltd., Horizon Therapeutics PLC, and Kitov Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Osteoarthritis Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Anatomy, market is studied across Hand Osteoarthritis, Hip Osteoarthritis, Knee Osteoarthritis, and Small Joint Osteoarthritis.
• Based on Drug Type, market is studied across Analgesics, Corticosteroids, Nonsteroidal Anti-inflammatory Drugs, and Viscosupplementation Agents. The Analgesics is further studied across Acetaminophen and Duloxetine. The Nonsteroidal Anti-inflammatory Drugs is further studied across Aspirin, Diclofenac, Ibuprofen, and Naproxen.
• Based on Route of Administration, market is studied across Oral Route, Parenteral Route, and Topical Route.
• Based on Purchasing Pattern, market is studied across Over-the-Counter Drugs and Prescription Drugs.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of osteoarthritis across the globe
    • 5.1.1.2. Potential demand for minimally invasive surgical procedures
    • 5.1.1.3. Growing geriatric population coupled with increasing sports injury worldwide
  • 5.1.2. Restraints
    • 5.1.2.1. Concern associated with adverse effects of NSAID
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging pharmaceuticals therapies for osteoarthritis
    • 5.1.3.2. Ongoing research and development in the osteoarthritis field
    • 5.1.3.3. Increasing governments supports towards the osteoarthritis treatment
    • 5.1.3.4. Rising healthcare expenditure per capita income in the emerging economies
  • 5.1.4. Challenges
    • 5.1.4.1. Rapid adoption of non-drug pain management therapies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Osteoarthritis Therapeutics Market, by Anatomy

• 6.1. Introduction
• 6.2. Hand Osteoarthritis
• 6.3. Hip Osteoarthritis
• 6.4. Knee Osteoarthritis
• 6.5. Small Joint Osteoarthritis

7. Osteoarthritis Therapeutics Market, by Drug Type

• 7.1. Introduction
• 7.2. Analgesics
  • 7.2.1. Acetaminophen
  • 7.2.2. Duloxetine
• 7.3. Corticosteroids
• 7.4. Nonsteroidal Anti-inflammatory Drugs
  • 7.4.1. Aspirin
  • 7.4.2. Diclofenac
  • 7.4.3. Ibuprofen
  • 7.4.4. Naproxen
• 7.5. Viscosupplementation Agents

8. Osteoarthritis Therapeutics Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral Route
• 8.3. Parenteral Route
• 8.4. Topical Route

9. Osteoarthritis Therapeutics Market, by Purchasing Pattern

• 9.1. Introduction
• 9.2. Over-the-Counter Drugs
• 9.3. Prescription Drugs

10. Osteoarthritis Therapeutics Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Americas Osteoarthritis Therapeutics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Osteoarthritis Therapeutics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Osteoarthritis Therapeutics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Almatica Pharma LLC
• 3. Anika Therapeutics, Inc.
• 4. Assertio Therapeutics, Inc.
• 5. Atnahs Pharma UK Limited
• 6. Bayer AG
• 7. Bioventus
• 8. Eli Lilly and Company
• 9. Ferring B.V.
• 10. Fidia Farmaceutici s.p.a.
• 11. Flexion Therapeutics, Inc.
• 12. GlaxoSmithKline PLC
• 13. Hanmi Pharm. Co., Ltd.
• 14. Horizon Therapeutics PLC
• 15. Kitov Pharmaceuticals Ltd.